profit from every $100 of sales.
$0$100
Maze Therapeutics
$35.45+1.55% today
+11.3% in 1 year
1-year low $22.391-year high $51.83
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
You pay $37.70 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Maze Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$131 million of profit last year.
SalesProfit
Maze Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Maze Therapeutics | 37.7× · Expensive | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.0× · Fair price | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Maze Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 168 | 0 | |
| – | – | – | – | |
| -111 | -99 | 58 | -143 | |
| -107 | -94 | 61 | -140 | |
| -115 | -100 | 52 | -131 | |
| -3.29 | -2.87 | 0.08 | -3.05 | |
| – | – | – | – | |
| – | – | 34.4% | – | |
| – | – | 31.2% | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 150 | 72 | 241 | 397 |
| Cash | 100 | 29 | 197 | 189 |
| Total debt | 32 | 50 | 27 | 23 |
| Total liabilities | 432 | 445 | 552 | 42 |
| -282 | -374 | -311 | 355 | |
| 35 | 35 | 44 | 43 | |
| – | – | – | -29.8% | |
| 40.7% | 26.9% | -16.8% | -36.9% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -99 | -87 | 76 | -112 | |
| 2 | 0 | 1 | 1 | |
| -101 | -87 | 75 | -113 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 7 | 9 | 10 | 16 |
Valuation
- 37.7×
- –
- –
- 4.2×
- 11.8×
- 26.3×
- 29.5×
- 3.8%
- 2.7%
- 0.0%
Profitability
- 92.0%
- 34.4%
- 31.2%
- -631.1%
- -33.2%
- -66.4%
- -36.6%
- -29.2%
- -33.6%
- 572.9%
Growth
- –
- –
- −250.7%
- –
- −0.6%
Financial health
- 1.1×
- 0.18
- 14.6%
- -154.8×
- 17.88
- 17.88
- 0.05
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 15%of 953
Top 6%of 877
Bottom 35%of 564
Top 28%of 988
What analysts expect
- Average price target
- $59.43
- Range
- $46.00 – $97.00
- 3 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 12, 2026 | -0.45 | -0.43 | −4.7% |
| Mar 25, 2026 | -0.65 | -0.73 | +11.0% |
| Nov 6, 2025 | -0.66 | -0.74 | +10.8% |
| Aug 12, 2025 | -0.77 | -0.79 | +2.5% |
| May 14, 2025 | -1.15 | -0.76 | −51.3% |
| Mar 31, 2025 | -18.32 | 0.45 | −4,171.1% |
| Sep 30, 2024 | -0.57 | – | – |
| Jun 30, 2024 | 3.18 | – | – |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
3/7Passes 3 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
52No pass
Benjamin Graham
38No pass
Philip Fisher
69Pass
Peter Lynch
100Pass
Joel Greenblatt
10No pass
Charlie Munger
60Pass
Terry Smith
58No pass
Questions about Maze Therapeutics
Is Maze Therapeutics a good stock to buy?
A strong, very profitable business, but the price is high. 3 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Maze Therapeutics AI analysis
What does Maze Therapeutics do?
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. It is in Biotechnology.
Does Maze Therapeutics pay a dividend?
No. Maze Therapeutics does not pay a dividend at the moment.
Is Maze Therapeutics stock halal?
Yes. Maze Therapeutics passes our halal screen: its business is permitted and its debt is 1% of its market value, under the 30% limit. How we check
How has Maze Therapeutics stock done over the past year?
Up 11.3% over the past twelve months, to $35.45. It traded between $22.39 and $51.83 and is 31.6% below its high.
Who are Maze Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Maze Therapeutics's.
Prices: daily closes to Nov 10, 2026. Fundamentals: company reports via invest-like data.